AstraZeneca's cancer drug, datopotamab deruxtecan, failed to meet targets in a Phase 3 trial, clouding the possibility of approval from the U.S. Food and Drug Administration. Shares were down 1.2% at ...

Board members from the European Central Bank are set to speak through the week, with Frank Elderson and Piero Cipollone ...

The AJ is delighted to announce the finalists of this year’s AJ Architecture Awards. The first to be revealed are in the ...

A new AstraZeneca drug has failed to extend significantly the lives of breast cancer patients in a blow to the company’s ambitions to hit an $80bn revenue target by 2030. Datopotamab deruxtecan ...

AstraZeneca said on Monday its experimental precision drug developed with Japan's Daiichi Sankyo did not significantly ...

Datopotamab deruxtecan is a TROP2-directed DXd ADC engineered by Daiichi Sankyo and co-developed by AstraZeneca and Daiichi Sankyo. The data pertaining to this compound will be presented at an ...

AstraZeneca's breast cancer drug datopotamab deruxtecan didn't show a statistical significance in overall survival compared with chemotherapy, results showed at a phase three trial.

AstraZeneca said on Monday its experimental precision drug developed with Daiichi Sankyo did not significantly improve ...

Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...

The vaccine FluMist, manufactured by MedImmune, which was acquired by AstraZeneca in 2007, was first approved by the FDA in 2003 for individuals between five and 49 years of age. Its approval has ...

Recent health news highlights key regulatory approvals and legal actions. The EU backs Novo Nordisk's Wegovy for an ...

The HBCU Week Foundation, a non-profit organization dedicated to supporting Historically Black Colleges and Universities ...